Evidence map›Paper›PMID 34690687›Full record

ArticleFrontiers in neuroscience2021

Monitoring Visual Cortical Activities During Progressive Retinal Degeneration Using Functional Bioluminescence Imaging.

Darryl Narcisse, Sourajit M Mustafi, Michael Carlson, Sanghoon Kim, Subrata Batabyal, Weldon Wright, Samarendra K Mohanty

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Darryl NarcisseNanoscope Technologies LLC, Bedford, TX, United States.
Sourajit M MustafiNanoscope Technologies LLC, Bedford, TX, United States.
Michael CarlsonNanoscope Technologies LLC, Bedford, TX, United States.
Sanghoon KimNanoscope Technologies LLC, Bedford, TX, United States.
Subrata BatabyalNanoscope Technologies LLC, Bedford, TX, United States.
Weldon WrightNanoscope Technologies LLC, Bedford, TX, United States.
Samarendra K MohantyNanoscope Technologies LLC, Bedford, TX, United States.

Funding

AMBIENT LIGHT ACTIVATABLE OPSIN BASED THERAPY FOR AGE-RELATED MACULAR DEGENERATIONR44EY025905 · NEI · NANOSCOPE TECHNOLOGIES, LLC · PI MOHANTY, SAMARENDRA KUMAR · 2018 to 2022
$3.7M
Targeted Nano-enhanced Optical Delivery of opsin for dry-AMD therapyR44EY031642 · NEI · NANOSCOPE TECHNOLOGIES, LLC · PI MOHANTY, SAMARENDRA KUMAR · 2020 to 2022
$2.1M
Bioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual systemR01EY028216 · NEI · NANOSCOPE TECHNOLOGIES, LLC · PI MOHANTY, SAMARENDRA KUMAR · 2018 to 2022
$2.0M
Broad-band opsin and targeted optical-delivery for retinitis pigmentosa treatmentR01EY025717 · NEI · NANOSCOPE TECHNOLOGIES, LLC · PI MOHANTY, SAMARENDRA KUMAR · 2016 to 2020
$1.7M
NEI NIH HHS R01 EY025717NEI NIH HHS R01 EY028216NEI NIH HHS R44 EY025905NEI NIH HHS R44 EY031642
6 · The paper itself

Abstract

Mouse models of inherited retinal degenerative diseases such as retinitis pigmentosa are characterized by degeneration of photoreceptors, which hinders the generation of signal to be transmitted to the visual cortex. By monitoring Ca

Indexed as

bioluminescencefunctional imagingmulti-characteristic opsinretinal degenerationvisually-evoked activity

Identifiers

PMID34690687
PMCPMC8530108
OpenAlexW3205604850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.